Pacific Biosciences of California reports prelim Q4, FY revenue above estimate
Source: SeekingAlpha
2026-01-12 09:18:12 ET
More on Pacific Biosciences of California
- Pacific Biosciences: Longer Reads, But Shorter Patience (Downgrade)
- Pacific Biosciences of California, Inc. 2025 Q3 - Results - Earnings Call Presentation
- Pacific Biosciences of California, Inc. (PACB) Q3 2025 Earnings Call Transcript
- PacBio narrows 2025 revenue guidance to $155M-$160M as consumables hit record and clinical focus intensifies
- Pacific Biosciences of California Non-GAAP EPS of -$0.12 beats by $0.02, revenue of $38.4M misses by $1.85M
Read the full article on Seeking Alpha
For further details see:
Pacific Biosciences of California reports prelim Q4, FY revenue above estimate
Pacific Biosciences of California Inc.
NASDAQ: PACB
PACB Trading
5.2% G/L:
$1.415 Last:
2,496,776 Volume:
$1.43 Open:
PACB Latest News
March 05, 2026 08:30:00 am
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
February 24, 2026 09:05:00 am
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
February 18, 2026 04:05:00 pm
PacBio to Participate in the TD Cowen 46th Annual Health Care Conference
PACB Stock Data
$549,471,524
294,359,745
0.64%
78
N/A
Biotechnology & Life Sciences
Healthcare
US
Menlo Park
